Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$131.49 USD

131.49
142,467

-0.94 (-0.71%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $131.54 +0.05 (0.04%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio

by Zacks Equity Research

Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes

by Zacks Equity Research

Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.

Veeva Systems' (VEEV) New Release to Address Supply-Chain Issues

by Zacks Equity Research

Veeva Systems' (VEEV) new cloud application is likely to improve efficiency and accelerate time-to-market by connecting systems and automating data aggregation, reviews and traceability.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.

Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) improving non-medical sales and a solid foothold in the broader MedTech space raise optimism about the stock.

Avantor's (AVTR) Tie-Up to Address Temperature-Specific Logistics

by Zacks Equity Research

Avantor's (AVTR) partnership is likely to meet the growing need among biopharma and life science companies for end-to-end solutions.

BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes

by Zacks Equity Research

BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.

Align Technology's (ALGN) New Feature to Boost Patient Experience

by Zacks Equity Research

Align Technology's (ALGN) introduction of the new SmartForce feature is expected to minimize the number of attachments while maintaining predictable treatment outcomes.

Strength Seen in DexCom (DXCM): Can Its 6.5% Jump Turn into More Strength?

by Zacks Equity Research

DexCom (DXCM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.

Why You Should Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation

by Zacks Equity Research

Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.

Masimo's (MASI) Inks Agreement to Improve Patient Outcomes

by Zacks Equity Research

Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.

Phibro (PAHC) Q4 Earnings Miss Estimates, Gross Margin Falls

by Zacks Equity Research

Robust performance across the Animal Health segment is encouraging for Phirbo (PAHC).

Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY24 Outlook

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both segments.

Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales

by Zacks Equity Research

Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.

Medtronic's (MDT) Inceptiv Spinal Cord Stimulator Gets CE Mark

by Zacks Equity Research

Medtronic's (MDT) Inceptiv SCS System is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals.

BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS

by Zacks Equity Research

The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.

LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes

by Zacks Equity Research

Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.

Charles River (CRL) Collaborates With Fondazione Telethon

by Zacks Equity Research

Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.